Výsledky vyhledávání - "Bruce, McCall"

Akademický článek

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)

Abstract Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, N

Externí odkaz: https://doaj.org/article/fa3f41ad888d41f5a1c759f8b6fa21b2

Zobrazit plný text záznamu

Akademický článek

Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

Autor: Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken

Publikováno v: Frontiers in Oncology, Vol 6 (2016)

Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to EGFR and HER3, inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody dependent cell mediated cytotoxicity. High tumor-expr

Externí odkaz: https://doaj.org/article/d89afeed3e904b81a4584162cf8e5c84

Zobrazit plný text záznamu

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials

Publikováno v: Cytotherapy. 24(7)

As cancer immunotherapies continue to expand across all areas of oncology, it is imperative to establish a standardized approach for defining and capturing clinically important toxicities, such as cytokine release syndrome (CRS). In this paper, we pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57d7f3db31555dcdaaef6afcc55cb85d
https://pubmed.ncbi.nlm.nih.gov/35219582

Zobrazit plný text záznamu

Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors

Autor: Maria Anderson, Steve Eppler, Bruce McCall, Eric Wakshull, Tony Pourmohamad, Colin D. Weekes, Ina Rhee, Weilan Ye, Alberto Bessudo, Anna Capasso, Rupal Desai, Priti S. Hegde, Mahrukh Huseni, Jill Fredrickson, Quyen Shon-Nguyen, Lee S. Rosen, Kit Man Wong

Publikováno v: Cancer Chemotherapy and Pharmacology. 82:339-351

MINT1526A is a monoclonal antibody that blocks the interaction of integrin alpha 5 beta 1 (α5β1) with its extracellular matrix ligands. This phase I study evaluated the safety and pharmacokinetics of MINT1526A with or without bevacizumab in patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::365f13cd1bcd4a2e00eebd4594b8be17
https://doi.org/10.1007/s00280-018-3622-8

Zobrazit plný text záznamu

Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy

Autor: Tina Nielsen, Krishna V. Komanduri, David Carlile, David Perez-Callejo, Bruce McCall, Antonia Kwan, Michelle Byrtek, Chi-Chung Li, Anton Belousov, Emily Piccione

Publikováno v: Blood. 138:1459-1459

Background: Cytokine release syndrome (CRS) is a potentially life-threatening toxicity caused by immune activation. CRS can be triggered non-specifically by T-cell engaging therapies. Risk factors for CRS are expected to be disease-specific and predi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb46423a05aef04ffe40fbc28592ebce
https://doi.org/10.1182/blood-2021-147303

Zobrazit plný text záznamu

Elektronická kniha

How Did I Get Here? : A Memoir

Autor: Bruce McCall

From his hardscrabble post-World War II Ontario childhood and coming of age to Mad Men-era New York City and the creative pinnacle of advertising, to the hallowed halls of Saturday Night Live and The New Yorker, Bruce McCall's personal and creat

Zobrazit plný text záznamu

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

Autor: Amy V. Kapp, Stephanie Royer-Joo, Lori J. Wirth, Antonio Jimeno, X. Wang, Tanguy Y. Seiwert, Jean-Pascal Machiels, Bruce McCall, Pol Specenier, Feby Mardjuadi, Elicia Penuel, Paul Clement, Andrea Pirzkall

Publikováno v: Cancer. 122:3803-3811

BACKGROUND This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97ef0b534bb09f451e0370104e1f425f
https://doi.org/10.1002/cncr.30256

Zobrazit plný text záznamu

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)

Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73fc28cc7c59c4759fd428fd7ccd9573
https://doi.org/10.1186/s40425-018-0351-9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání